or Try an Advanced Search...

    ETF Components for HELX - Franklin Genomic Advancements ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    VRTX D -0.35 5.94
    KRYS C 2.42 4.70
    NTRA A 1.12 4.64
    LLY F -0.90 4.63
    REGN F 0.36 4.30
    MEDP F 4.86 4.07
    TMO D 0.39 4.01
    DHR D 0.46 3.99
    UTHR C 0.77 2.75
    AZN F 1.13 2.34
    CDNS B 0.81 2.34
    CTVA C 3.83 2.29
    CRL D 3.41 2.23
    BNTX D 5.89 2.21
    A F 2.41 2.11
    IONS F -4.38 2.10
    INSM C 1.08 2.08
    RVTY D -1.06 2.01
    ALNY D -0.68 1.98
    QGEN D 0.43 1.96
    BRKR F 5.51 1.94
    SRPT F -0.88 1.50
    RARE F 0.24 1.46
    RCKT F -0.08 1.42
    TWST F 2.32 1.27
    LGND C 4.67 1.27
    ICLR D 4.52 1.25
    EXAS D 1.59 1.20
    LH B 0.99 1.15
    IQV F 1.32 1.08
    RGEN D 1.03 1.08
    BEAM D -3.31 1.03
    TECH F 3.30 1.01
    VYGR F 1.49 0.99
    AZTA D 2.31 0.95
    NBIX C 1.39 0.94
    BBIO F 1.04 0.91
    RXRX D -3.60 0.69
    MRNA F 3.59 0.66
    BIO C 0.28 0.59
    VCYT B 0.23 0.56
    DVAX C 1.48 0.53
    NTLA F 5.11 0.51
    DOCS C -3.73 0.51
    CDMO A 0.25 0.51
    CRSP D -2.40 0.50
    AVTR F 0.65 0.46
    BMY B 0.48 0.36
    CRNX B 1.50 0.25
    BMRN F 1.52 0.20
    ARE F 1.54 0.15
    SLP F 8.09 0.11
    FDMT F -4.64 0.10

    Represented by ETF Holdings

    Keywords: Biotechnology S&P 500 Life Sciences Biology Biopharmaceutical Medicine Cancer Clinical Development Acid Drug Discovery Infectious Diseases Lab Testing Amyloid Antibodies Cholesterol In Vitro Nasdaq 100 Rare Diseases Amyloidosis Asthma
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Agricultural Inputs Health Information Services Health Information Services REIT - Office Semiconductor Equipment & Materials Software - Application Specialty Chemicals

    Recent News for Franklin Genomic Advancements ETF & its Holdings

    Date Stock Title
    Nov 21 TECH Could Another Magnificent 7 Stock Beat Nvidia In 2025? Poll Says Not Likely, 27% Pick This Potential Winner
    Nov 21 TECH Nvidia's Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?
    Nov 21 LLY Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 TECH Reddit Suffers Second Disruption In Two Days
    Nov 21 AZN AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
    Nov 21 TECH IBM Spin-Off Kyndryl Announces $300 Million Buyback: What's Next For KD Stock?
    Nov 21 MRNA Major companies that are also popular short-selling stocks
    Nov 21 BMY Major companies that are also popular short-selling stocks
    Nov 21 ICLR Should You Retain Your Conviction in Icon Plc (ICLR)?
    Nov 21 TECH Temu Parent PDD Stock Tumbles After Q3 Profit Miss, Company Cites Intensified Competition and External Challenges
    Nov 21 TECH How To Earn $500 A Month From Intuit Stock Ahead Of Q1 Earnings
    Nov 21 BMY Is Bristol Myers Squibb Stock a Buy?
    Nov 21 AZN We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
    Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
    Nov 21 AZN 3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
    Nov 21 ICLR Baird cuts Icon target, names ‘Bullish Fresh Pick’
    Nov 21 TECH Tesla Registrations Drop By Over 20% In October In EU, Possibly Hindering Its 2024 Global EV Delivery Target
    Nov 21 AZN AstraZeneca upgraded to Neutral from Sell at UBS
    Nov 21 BMY Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
    Nov 21 AZN AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg
    Seeks capital appreciation by investing in innovative companies related to genomic-based technologies designed to enhance the quality of life. Provides access to companies benefitting from or facilitating the use of new research including DNA sequencing, gene editing and personalized medicine Uses bottom-up fundamental research conducted by dedicated, industry-specific analysts to identify disruptive business models at the right stage for investment Actively managed by a seasoned portfolio management team that is based in Silicon Valley and has a long history of investing in the craft of innovation
    Exchange Traded Fund ETF Biotechnology Life Sciences Biology Emerging Technologies Molecular Biology Genetics Portfolio Management Quality Of Life Personalized Medicine DNA DNA Sequencing
    Back to the Main HELX Page...